← Tonghua Dongbao Pharmaceutical overview

Tonghua Dongbao Pharmaceutical vs MannKind: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Tonghua Dongbao Pharmaceutical Co Ltd (600867.CG)

Q3 2026
▲2▼2

FDA approval and strong H1 profit offset by high shareholder pledges

  • US FDA approval opens overseas market Tonghua Dongbao's co-developed insulin aspart injection won US FDA approval, letting it sell in the world's biggest insulin market. Novo Nordisk's US insulin aspart sales were about $1.1 billion last year, so this is a real long-term growth opening, not just a headline.

    This is the biggest new positive force, opening a large new market for the company's insulin products.

  • First-half profit jumps 37% on insulin analogue sales First-half 2026 revenue rose 11.13% to 1.553 billion yuan and net profit rose 37.32% to 296 million yuan. Strong sales of insulin glargine and aspart drove domestic growth, and second-quarter profit rose 55.5%. This shows the core business is performing well.

    The interim results are the clearest evidence of underlying business strength and directly support the stock's value.

  • Controlling shareholder pledges over 93% of its shares Dongbao Group repeatedly released and re-pledged tens of millions of shares, leaving 93.94% of its holdings pledged. That is a warning sign: if the share price falls sharply, the shareholder could face margin calls or forced selling, which would hurt ordinary investors.

    This is the main risk weighing on the stock and a real counterweight to the good news.

  • Project termination and impairment slightly reduce profit Tonghua Dongbao scrapped its THDBH110 capsule development project and wrote off 16.89 million yuan, cutting first-half profit by that amount. It is a small hit next to the 296 million yuan profit, but it shows some pipeline bets are not paying off.

    This is a modest but real negative that partly offsets the strong earnings and shows pipeline risk.

August 2026
▲2▼2

FDA approval and strong H1 profit offset by high shareholder pledges

  • US FDA approval opens overseas market Tonghua Dongbao's co-developed insulin aspart injection won US FDA approval, letting it sell in the world's biggest insulin market. Novo Nordisk's US insulin aspart sales were about $1.1 billion last year, so this is a real long-term growth opening, not just a headline.

    This is the biggest new positive force, opening a large new market for the company's insulin products.

  • First-half profit jumps 37% on insulin analogue sales First-half 2026 revenue rose 11.13% to 1.553 billion yuan and net profit rose 37.32% to 296 million yuan. Strong sales of insulin glargine and aspart drove domestic growth, and second-quarter profit rose 55.5%. This shows the core business is performing well.

    The interim results are the clearest evidence of underlying business strength and directly support the stock's value.

  • Controlling shareholder pledges over 93% of its shares Dongbao Group repeatedly released and re-pledged tens of millions of shares, leaving 93.94% of its holdings pledged. That is a warning sign: if the share price falls sharply, the shareholder could face margin calls or forced selling, which would hurt ordinary investors.

    This is the main risk weighing on the stock and a real counterweight to the good news.

  • Project termination and impairment slightly reduce profit Tonghua Dongbao scrapped its THDBH110 capsule development project and wrote off 16.89 million yuan, cutting first-half profit by that amount. It is a small hit next to the 296 million yuan profit, but it shows some pipeline bets are not paying off.

    This is a modest but real negative that partly offsets the strong earnings and shows pipeline risk.

Latest
▲2▼2

FDA approval and strong H1 profit offset by high shareholder pledges

  • US FDA approval opens overseas market Tonghua Dongbao's co-developed insulin aspart injection won US FDA approval, letting it sell in the world's biggest insulin market. Novo Nordisk's US insulin aspart sales were about $1.1 billion last year, so this is a real long-term growth opening, not just a headline.

    This is the biggest new positive force, opening a large new market for the company's insulin products.

  • First-half profit jumps 37% on insulin analogue sales First-half 2026 revenue rose 11.13% to 1.553 billion yuan and net profit rose 37.32% to 296 million yuan. Strong sales of insulin glargine and aspart drove domestic growth, and second-quarter profit rose 55.5%. This shows the core business is performing well.

    The interim results are the clearest evidence of underlying business strength and directly support the stock's value.

  • Controlling shareholder pledges over 93% of its shares Dongbao Group repeatedly released and re-pledged tens of millions of shares, leaving 93.94% of its holdings pledged. That is a warning sign: if the share price falls sharply, the shareholder could face margin calls or forced selling, which would hurt ordinary investors.

    This is the main risk weighing on the stock and a real counterweight to the good news.

  • Project termination and impairment slightly reduce profit Tonghua Dongbao scrapped its THDBH110 capsule development project and wrote off 16.89 million yuan, cutting first-half profit by that amount. It is a small hit next to the 296 million yuan profit, but it shows some pipeline bets are not paying off.

    This is a modest but real negative that partly offsets the strong earnings and shows pipeline risk.

MannKind Corp (MNKD)

Q3 2026
▲4▼1

MannKind's pipeline wins and record sales offset dilution and royalty threat

  • Afrezza pediatric approval drives 20% gain The FDA approved Afrezza, MannKind's inhaled insulin, for children aged 6 and up with diabetes. This opens a new market of over 350,000 young patients, and the stock has already risen about 20% since the news. Analysts see more upside ahead.

    This is a major new approval that expands the market for MannKind's flagship product and has already boosted the stock.

  • Competitor Tresmi threatens Tyvaso DPI royalty United Therapeutics introduced Tresmi, a competing inhaler for the same condition as Tyvaso DPI. MannKind earns a 9% royalty on Tyvaso DPI sales, which brought in $32.7 million last quarter. If Tresmi takes market share, that royalty income could shrink, hurting MannKind's profits.

    This is a new competitive threat that could reduce a significant and reliable revenue stream for MannKind.

  • $50 million private placement dilutes shares but funds CVR MannKind raised $50 million by selling new shares and warrants to investors led by Frazier Life Sciences. This brings in cash to fund a $45 million payment tied to the Furoscix ReadyFlow approval, but it also increases the number of shares outstanding, which can lower the value of each existing share.

    This financing is a key capital event that affects MannKind's cash position and share count, with both positive and negative implications.

  • Furoscix ReadyFlow approved and launched The FDA approved Furoscix ReadyFlow, an at-home autoinjector for fluid overload in heart failure and kidney disease. This adds a new product to MannKind's lineup and triggered a $45 million payment to the original developer. Early sales are growing quickly, up 43% from the prior quarter.

    This is a new product approval that diversifies revenue and has already started contributing to growth.

  • Inhaled nintedanib shows positive Phase 1b results MannKind's inhaled nintedanib for idiopathic pulmonary fibrosis (IPF) passed a mid-stage safety test, with no serious side effects. A larger Phase 2 trial is now enrolling patients. If successful, this could become a major new product, but it is still years from market.

    This pipeline progress adds long-term growth potential and validates MannKind's inhalation technology.

  • Record Q2 revenue and all 2026 catalysts achieved MannKind reported second-quarter revenue of $109.4 million, up 43% from a year ago, driven by strong product sales and royalties. The company hit all three of its 2026 goals: Afrezza pediatric approval, Furoscix ReadyFlow approval, and positive nintedanib data. It ended the quarter with $161 million in cash.

    This earnings report confirms strong financial performance and execution, which supports the stock's value.

July 2026
▲4▼1

MannKind's pipeline wins and record sales offset dilution and royalty threat

  • Afrezza pediatric approval drives 20% gain The FDA approved Afrezza, MannKind's inhaled insulin, for children aged 6 and up with diabetes. This opens a new market of over 350,000 young patients, and the stock has already risen about 20% since the news. Analysts see more upside ahead.

    This is a major new approval that expands the market for MannKind's flagship product and has already boosted the stock.

  • Competitor Tresmi threatens Tyvaso DPI royalty United Therapeutics introduced Tresmi, a competing inhaler for the same condition as Tyvaso DPI. MannKind earns a 9% royalty on Tyvaso DPI sales, which brought in $32.7 million last quarter. If Tresmi takes market share, that royalty income could shrink, hurting MannKind's profits.

    This is a new competitive threat that could reduce a significant and reliable revenue stream for MannKind.

  • $50 million private placement dilutes shares but funds CVR MannKind raised $50 million by selling new shares and warrants to investors led by Frazier Life Sciences. This brings in cash to fund a $45 million payment tied to the Furoscix ReadyFlow approval, but it also increases the number of shares outstanding, which can lower the value of each existing share.

    This financing is a key capital event that affects MannKind's cash position and share count, with both positive and negative implications.

  • Furoscix ReadyFlow approved and launched The FDA approved Furoscix ReadyFlow, an at-home autoinjector for fluid overload in heart failure and kidney disease. This adds a new product to MannKind's lineup and triggered a $45 million payment to the original developer. Early sales are growing quickly, up 43% from the prior quarter.

    This is a new product approval that diversifies revenue and has already started contributing to growth.

  • Inhaled nintedanib shows positive Phase 1b results MannKind's inhaled nintedanib for idiopathic pulmonary fibrosis (IPF) passed a mid-stage safety test, with no serious side effects. A larger Phase 2 trial is now enrolling patients. If successful, this could become a major new product, but it is still years from market.

    This pipeline progress adds long-term growth potential and validates MannKind's inhalation technology.

  • Record Q2 revenue and all 2026 catalysts achieved MannKind reported second-quarter revenue of $109.4 million, up 43% from a year ago, driven by strong product sales and royalties. The company hit all three of its 2026 goals: Afrezza pediatric approval, Furoscix ReadyFlow approval, and positive nintedanib data. It ended the quarter with $161 million in cash.

    This earnings report confirms strong financial performance and execution, which supports the stock's value.

Latest
▲4▼1

MannKind's pipeline wins and record sales offset dilution and royalty threat

  • Afrezza pediatric approval drives 20% gain The FDA approved Afrezza, MannKind's inhaled insulin, for children aged 6 and up with diabetes. This opens a new market of over 350,000 young patients, and the stock has already risen about 20% since the news. Analysts see more upside ahead.

    This is a major new approval that expands the market for MannKind's flagship product and has already boosted the stock.

  • Competitor Tresmi threatens Tyvaso DPI royalty United Therapeutics introduced Tresmi, a competing inhaler for the same condition as Tyvaso DPI. MannKind earns a 9% royalty on Tyvaso DPI sales, which brought in $32.7 million last quarter. If Tresmi takes market share, that royalty income could shrink, hurting MannKind's profits.

    This is a new competitive threat that could reduce a significant and reliable revenue stream for MannKind.

  • $50 million private placement dilutes shares but funds CVR MannKind raised $50 million by selling new shares and warrants to investors led by Frazier Life Sciences. This brings in cash to fund a $45 million payment tied to the Furoscix ReadyFlow approval, but it also increases the number of shares outstanding, which can lower the value of each existing share.

    This financing is a key capital event that affects MannKind's cash position and share count, with both positive and negative implications.

  • Furoscix ReadyFlow approved and launched The FDA approved Furoscix ReadyFlow, an at-home autoinjector for fluid overload in heart failure and kidney disease. This adds a new product to MannKind's lineup and triggered a $45 million payment to the original developer. Early sales are growing quickly, up 43% from the prior quarter.

    This is a new product approval that diversifies revenue and has already started contributing to growth.

  • Inhaled nintedanib shows positive Phase 1b results MannKind's inhaled nintedanib for idiopathic pulmonary fibrosis (IPF) passed a mid-stage safety test, with no serious side effects. A larger Phase 2 trial is now enrolling patients. If successful, this could become a major new product, but it is still years from market.

    This pipeline progress adds long-term growth potential and validates MannKind's inhalation technology.

  • Record Q2 revenue and all 2026 catalysts achieved MannKind reported second-quarter revenue of $109.4 million, up 43% from a year ago, driven by strong product sales and royalties. The company hit all three of its 2026 goals: Afrezza pediatric approval, Furoscix ReadyFlow approval, and positive nintedanib data. It ended the quarter with $161 million in cash.

    This earnings report confirms strong financial performance and execution, which supports the stock's value.